Adagio Medical Holdings (ADGM) Corporate presentation summary

Leadership and team experience

• Leadership team brings over 200 years of combined med tech experience, with backgrounds at major industry players.

Market opportunity and positioning

• VT ablation market estimated at $5.8B globally, with only 6% current penetration and significant growth potential.

• Approximately 1.6M global patients are eligible for VT ablation annually, with 200K in the U.S.

• Established U.S. reimbursement and breakthrough device designation support market access.

Technology and clinical differentiation

• Ultra Low Temperature Ablation (ULTA) system purpose-built for VT, offering deeper, more durable lesions and improved safety.

• Demonstrated >2x lesion depth compared to radiofrequency, with minimal attenuation in scar tissue.

• No irrigation required, simplifying procedures and reducing risk in fluid-compromised patients.